Pharmaceutical compositions for inhibiting angiogenesis

Abstract

The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

What is claimed is: 
     
         1 . A pharmaceutical composition for inhibiting angiogenesis, comprising:
 an effective amount of a lignan as an effective ingredient, wherein a formula of the lignin is shown as Formula (I):   
       
         
           
           
               
               
           
         
         wherein R 1  is —H or —OCH 3 , R 2  is —H or —OH, R 3  is —H, —OH or β-O-glucoside, and R 4  is —H or —OCH 3 . 
       
     
     
         2 . The pharmaceutical composition for inhibiting angiogenesis as claimed in  claim 1 , wherein the lignin comprises yatein, 5′-desmethoxyyatein (bursehernin), 7′, 7′-dihydroxy bursehernin, 5 ′-methoxyyatein, podorhizol or podorhizol 4′-o-β-D-glucopyranoside. 
     
     
         3 . The pharmaceutical composition for inhibiting angiogenesis as claimed in  claim 1 , further comprising a pharmaceutically acceptable carrier or salt.